Trileptal
Product Images NDC 54868-4836

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trileptal (NDC 54868-4836). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of 150 mg Package Label (4836)

Label for Trileptal 150 mg tablets by Physicians Total Care, Inc. Contains 30 tablets. The active ingredient is oxcarbazepine. The label includes dosage instructions, storage information, a barcode, lot number, and expiration date.*

FDA Label Image

Image Of 300 mg Package Label (4837)

Label for Trileptal 300 mg tablets by Physicians Total Care, Inc. The label shows the proprietary name Trileptal and the active ingredient oxcarbazepine. It contains 30 tablets per container. The label includes warnings such as Federal law prohibiting dispensing without prescription, storage instructions, and a lot number and expiration date area.*

FDA Label Image

Oxcarbazepine Structural Formula. (Trileptal 01)

Chemical structure of the active ingredient found in Trileptal, as provided by Physicians Total Care, Inc. The diagram shows the molecular structure with rings and bonding, including oxygen and nitrogen atoms represented.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Exit Rate By Treatment Group. (Trileptal 02)

A Kaplan-Meier survival curve displaying exit rates over time from day 2 to day 11, comparing two treatment groups: Oxcarbazepine and Placebo. The vertical axis shows exit rates from 0 to 1.0, and the log-rank test p-value is 0.0001, indicating a statistically significant difference between the groups.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group. (Trileptal 03)

A Kaplan-Meier plot depicting seizure rate over time in days from first use to first seizure for two treatment groups: Trileptal (solid line) and placebo (dashed line). The graph includes a log-rank test p-value of 0.046, indicating statistical comparison between the groups.*

FDA Label Image

Figure 3 Kaplan-meier Estimates Of Exit Rate By Treatment Group. (Trileptal 04)

A Kaplan-Meier curve chart depicting 'time to exit' over days for two treatment groups labeled as HIGH and LOW. The x-axis represents time in days from 0 to approximately 130, and the y-axis indicates the exit rate from 0.0 to 1.0. The chart includes a log-rank test p-value of 0.0001, showing a statistically significant difference between the two groups, with the LOW group exiting faster than the HIGH group.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Exit Rate By Treatment Group. (Trileptal 05)

A Kaplan-Meier survival curve comparing time to exit (in days) between two treatment groups labeled HIGH and LOW. The y-axis represents the exit rate, and the x-axis represents time in days up to 130 days. A log-rank test p-value of 0.0001 is shown, indicating a statistically significant difference between the groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.